"This technology brings STI testing to target populations":

Opportunities and challenges with chlamydia and gonorrhoea point of care testing in a peer-led community service

Bell SFE¹, <u>Coffey L</u>², Redmond AM^{2,3}, Gilks CF⁴, Debattista J⁵, Whiley DM¹, Oliveira C², Warner M², Dean JA⁴

¹UQ Centre for Clinical Research, The University of Queensland, Herston, Australia, ²Queensland Positive People, East Brisbane, Australia, ³Royal Brisbane and Women's Hospital, Metro North Health, Herston, Australia, ⁴School of Public Health, The University of Queensland, Herston, Australia, ⁵Metro North Public Health Unit, Metro North Health, Windsor, Australia





Always was, Always will be.




12



RAPID

- RAPID is a peer-led community-based sexual health clinic
- We provide asymptomatic screening for STIs:
 - Immunochromatographic testing for Human Immunodeficiency Virus and Treponema pallidum
 - Nucleic acid amplification testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*







RAPID


- A public health intervention seeking to:
 - address barriers to testing uptake
 - deliver health promotion on a combination of prevention strategies for people at risk of HIV and other STIs
- Clinical oversight and governance provided by an infectious diseases physician and through several committees








Client demographics



Abbott Determine HIV Early Detect

- Abbott Determine Syphilis TP
- Cepheid GeneXpert Xpert CT/NG Assay
- n = **8,961**

RAPID: Gender & Sexual Partners, Jul - Dec 2022









Behavioural risk factors

RAPID: Number of Sexual Partners, Sep 2022 -Feb 2023




RAPID: Condom Usage, Sep 2022 - Feb 2023







Growth associated with increased testing provision



2014

• Service established - HIV POCT

2015

• Introduction of syphilis POCT

2017

Introduction of CT/NG POCT





Case for model expansion: analytical validity

	Chlamydia ¹				Gonorrhoea ¹			
	Sensitivity (%)	Specificity (%)	PPV ^ (%)	NPV ^ (%)	Sensitivity (%)	Specificity (%)	PPV # (%)	NPV # (%)
Urine (male)	98.5	99.8	98.1	99.8	98.3	99.9	98.2	99.9
Urine (female)	98.1	99.8	98.1	99.8	94.4	>99.9	98.2	99.7
Pharyngeal swab	95.9	99.7	97.1	99.6	94.7	98.8	81.8	99.7
Rectal swab	86.0	99.4	93.7	98.5	91.2	99.6	92.9	99.5



GeneXpert® X VI System processing unit – 16 module

instrument




^ CT prevalence 9.5%# NG prevalence 5.4%



1. Cepheid. Data Sheet - XPERT CT/NG. Cepheid; 2018 [cited 2018 09/01/2018]

Case for model expansion: clinical validity



- HIV seroconversion up to **x5** greater in presence of other STI ³
- Chlamydia detected in 1 in 20 young people screened 4
- Gonorrhoea reduced
 susceptibility to first-line
 antibiotic treatment 4
- **3-monthly CT & NG testing** for asymptomatic MSM⁵



 National Notifiable Diseases Surveillance System 3. Fleming DT, Wasserheit JN. Sex Transm Infect 1999; 75:3–17. 4. Australian STI Management Guidelines for use in Primary Care 5. Australian STIGMA Guidelines 2019, NSWSTI Programs Unit



Case for model expansion: clinical utility

- Engagement from high risk populations⁶
 - **64.7%** of MSM did not meet testing guidelines
 - 2x greater CT & NG coinfection in clients tested at SOPV venues

- Effective model⁶
 - **27.3%** infections would not have been detected
 - **98.4%** informed of result < 24hrs and linked into care

- Acceptable to clients⁶
 - 99.3% accepted CT & NG testing at 1st visit
 - **98.4%** satisfied with service

"This sort of technology really enables us to bring STI testing to target populations"


– Peer tester





Improving affordability through specimen pooling

Individual specimens ХЗ Pooled specimens X 1



Original RAPID protocol – 7 ml urine volume⁷

CSIRO PUBLISHING

Sexual Health, 2020, 17, 15–21 https://doi.org/10.1071/SH19028

> Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care

Steven G. Badman^{A,H,*}, Sara F. E. Bell^{B,*}, Judith A. Dean^B, Jime Lemoire^C, Luke Coffey^C, Joseph Debattista^D, Andrew M. Redmond^{C,E}, Owain D. Williams^B, Charles F. Gilks^{B,†} and David M. Whiley^{F,G,†}

Sensitivity CT 90.0% NG 89.7%

Revised RAPID protocol – 1 ml urine volume⁸

Research letter

Improved sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near point of care

(b) Judith Ann Dean¹, Sara Fiona Elizabeth Bell¹, Luke Coffey², Joseph Debattista³, Steven Badman⁴, Andrew M Redmond^{2, 5}, David M Whiley^{6, 7}, Jime Lemoire², Owain David Williams¹, Chris Howard², Charles F Gilks¹

Sensitivity CT 98.0% NG 93.2%



 7. Badman SG et al. Sex Health 2020;17(1):7.
 8. Dean JA et al. Sexually Transmitted Infections 2021;97(6):471-2.
 Research Approvals: The University of Queensland Human Ethics Research Committee: UQHREC 2016001764 & Therapeutic Goods Administration Clinical Trial Notification Scheme Clinical Trial Number: 00812-1



Operationalising mPOCT

- RAPID's use of the GeneXpert system is considered "offlabel"
 - Proceeds in the setting of research under the TGA's Clinical Trial Notification Scheme (CTN scheme)
- This approach is unsustainable in terms of funding and future certainty

- A National Association of Testing Authorities accreditation process was investigated
 - Deemed unsuitable due to capital outlay and complexity
- Alternate medical testing model subverts success of community-led approach





Other Challenges

- Surveillance
 - No direct notification of notifiable conditions

Lack of alternative CT/NG POCT

- Not Australian approved
- Limited anatomical sites
- Paper based test poor performance

Additional resourcing requirements

- Training
- Data management
- Providing result and referrals

• Cost

- Community-based organisation funding models
- Technology, cartridges
- Additional staff

Performance criteria

- Extended test development time >30 minutes⁹
- No antimicrobial susceptibility POCT for NG





Summary

- Community-based CT/NG POC testing:
 - improves access for high-risk populations
 - acceptable to clients and staff
 - implementation limited by regulatory requirements and cost
- Stakeholder collaboration required to support integration into STI management pathways









GeneXpert Advisory Committee

The University of Queensland (UQ)

- A/Prof Judith Dean (POCHE)
- Prof Charles Gilks (UQ SPH)
- Sara Bell (UQCCR)
- A/Prof David Whiley (UQCCR)
- Cepheid
 - Dr Steven Badman

The University of New South Wales (UNSW)

• Prof Rebecca Guy (Kirby Institute)

- Queensland Positive People (QPP)
 - Melissa Warner
 - Luke Coffey
 - Cassio Oliveira

Metro North Health

- Dr Joseph Debattista
- A/Prof Andrew Redmond
- Dr Eugene Priscott





Disclosure of Interests

- QPP is funded by the Queensland Government
- Cepheid provided GeneXpert-XVI instrument and Xpert CT/NG assay cartridges
- Metro North Health provided funding via their Seed and Link programs
- Support provided through the Queensland Professorial Chair in Blood-Borne Virus and Sexually Transmissible Infections
- Dr Steven Badman is a RAPID GeneXpert research committee member, a former employee of The Kirby Institute for Infection and Immunity in Society at UNSW, and is currently employed by Cepheid.





References

- 1. Cepheid. Data Sheet XPERT CT/NG. Cephid; 2018 [cited 2018 09/01/2018]. Available from: <u>http://www.cepheid.com/administrator/components/com_productcatalog/library-files/c79b33a30737d79ec2275420913b888f-e6faea01628d163d8116a0af9ee201b4-CTNG-DATASHEET-400-02.pdf</u>
- 2. Department of Health and Aged Care. National Notifiable Diseases Surveillance System (NNDSS) data visualisation tool. Canberra: Australian Government; 2023 [updated 14 December 2022; cited 2023 1 March]. Available from: https://nindss.health.gov.au/pbi-dashboard/
- 3. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sexually Transmitted Infections 1999;75(1):3.
- 4. Ong JJ, Bourne C, Dean JA, Ryder N, Cornelisse VJ, Murray S, et al. Australian sexually transmitted infection (STI) management guidelines for use in primary care 2022 update. Sexual Health 2023;20(1):1-8.
- 5. STIs in Gay Men Action Group (STIGMA). Australian Sexually Transmitted Infection and HIV Testing Guidelines 2019: For asymptomatic men who have sex with men. STI's In Gay Men Action Group; 2019 [cited 2020 23 June]. Available from: <u>https://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Guidelines2019_Final-1.pdf</u>
- 6. Bell SFE, Coffey L, Debattista J, Badman SG, Redmond AM, Whiley DM, et al. Peer-delivered point-of-care testing for Chlamydia trachomatis and Neisseria gonorrhoeae within an urban community setting: a cross-sectional analysis. Sex Health 2020;17(4):359-67.
- 7. Badman SG, Bell SFE, Dean JA, Lemoire J, Coffey L, Debattista J, et al. Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care. Sex Health 2020;17(1):7.
- 8. Dean JA, Bell SFE, Coffey L, Debattista J, Badman S, Redmond AM, et al. Improved sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near point of care. Sexually Transmitted Infections 2021;97(6):471-2.
- 9. Fuller SS, Clarke E, Harding-Esch EM. Molecular chlamydia and gonorrhoea point of care tests implemented into routine practice: Systematic review and value proposition development. PLoS One 2021;16(11):e0259593



